CoaguChek Pro II combines two tests in a single device
Read more
Carestream Health makes converting to DR easy and affordable with the launch of its CARESTREAM DRX-Transportable System/Lite. This system equips facilities to convert room-based or mobile imaging systems to DR through use of a wireless tablet PC that gives users complete control of the X-ray system and displays diagnostic images as they are acquired. Control from the wireless tablet eliminates the need to interface with a generator and use a cable connection, which delivers exceptional flexibility and saves both time and money. An access point in the detector communicates with the access point in the tablet to create a flexible solution that enhances workflow. The ability to quickly and easily convert CR systems to DR with the use of Carestream’s wireless tablet offers significant advantages for healthcare providers. The lightweight wireless tablet equips users to capture DR exams from any room-based or mobile imaging system while moving freely throughout the radiology department and the hospital. This system uses a virtual access point in the DRX detector to manage image capture and display images on the tablet. The tablet PC is self-powered and rechargeable. It has a 12-inch touch screen and weighs just 3.6 pounds (1.63 Kg). This new system is available in the United States, Canada, Europe and selected countries around the world.
Read more
Philips’ next generation interventional oncology solution OncoSuite enables physicians to provide analysis and minimally invasive, targeted treatment of tumour lesions reducing the impact to healthy tissue. It offers clinicians a better view of the treatment targets for informed decision making, while performing the procedure. While OncoSuite can be used for a number of different cancers including bone, kidney and lung, the system and its specific tools have been optimized for the treatment of patients with liver cancer. Given the steady increase in the prevalence of non-alcoholic fatty liver disease and liver cancer, the development and availability of new technology is much needed to provide interventional oncologists with a breakthrough that allows best possible treatment for these patients. What matters most in these cases, is the ability to visualize the liver tumours, even small ones, during the procedure and to approach them in a very targeted way to maximize the therapeutic outcome, while avoiding the destruction of healthy liver tissue. OncoSuite is designed to help physicians see, reach and treat liver cancer in a better way. OncoSuite enhances tumour embolization and ablation procedures with Philips’ interventional X-ray systems. It is the only platform in the industry that supports both procedures, enabling physicians to target multiple tumour lesions simultaneously. OncoSuite comprises the company’s innovative product offerings for enhanced imaging (XperCT Dual), live 3D image guidance for tumour embolization (EmboGuide) and live 3D image guidance for tumour ablation (XperGuide). Minimally invasive, image-guided interventional oncology procedures are a highly effective option for patients who cannot be treated through conventional techniques such as surgery, chemotherapy or radiation therapy. Interventional oncology procedures are rapidly increasing and OncoSuite provides the first complete interventional oncology portfolio for interventional radiologists, enabling physicians to see the entire tumour and its feeder vessels to directly target treatment avoiding healthy tissue. The innovative Open Trajectory function within XperCT Dual enables better centering of the liver with significantly improved visualization during the procedure of peripheral hepatic tumours in a single sweep. This feature provides a more targeted field of view making it possible to effectively scan larger patients. Previously, with the traditional geometric movement of the C-arm of the interventional X-ray system, part of the liver image was truncated and larger patients required multiple scans to visualize tumours in the periphery of the liver. Embolization procedures involve blocking the arteries feeding a tumour with beads to deprive it of nutrients and oxygen. They require the insertion of a catheter, which must be guided to the tumour site with the aid of live image-guidance. BTG (Biocompatibles UK Ltd) and Philips have been working in close collaboration on the visualization benefits of radio-opaque beads in combination with image-guided therapy. Together the companies have calibrated LC Bead LUMI and Philips Live Image Guidance Software to help interventional radiologists and multi-disciplinary teams to visualize better treatment options for patients with liver cancer. As a result, the next generation OncoSuite also features the world’s first optimized imaging for LC Bead LUMI that provides real-time visible confirmation of bead location during embolization procedures. In addition, the new Wiper Movement functionality improves workflow with automatic dual phase imaging, helping physicians to acquire two 3D cone beam CT datasets at different times of the procedure in a single step.
Read more
Hitachi Aloka has developed two different styles of diagnostic ultrasound systems to meet these needs. ARIETTA Precision supports surgical treatment and acute healthcare, while ARIETTA Prologue has been designed especially for the POC (Point of Care) ultrasound market where often new users are looking for ultrasound to provide better chronic and community healthcare. ARIETTA Precision has a slim profile with a large 21.5
Read more
The latest addition to the Stat Profile product line, Stat Profile Prime ES, has gained CE mark certification for release in CE regulated countries. Prime ES incorporates Nova Biomedical’s innovative no-maintenance sensor card technology for a smaller, faster, and less expensive electrolyte analyser. Compact and lightweight, Prime ES provides a comprehensive electrolyte profile including Na, K, Cl, iCa, and iMg in just 60 seconds from 50 microliters of whole blood. Stat Profi le Prime’s no-maintenance technology comprises a single MicroSensor Card that contains all sensors for Na, K, Cl, iCa, and iMg with a 32-day use life, and a reagent cartridge containing all calibration reagents. The MicroSensor Card and reagent cartridge are both maintenance free and easily replaced in seconds. This design optimizes the life of each, improves analyser uptime, and reduces costs. Credit card-sized, the MicroSensor Card is always calibrated and ready to deliver a stat electrolyte profile. Stat Profile Prime’s Clot Block sample flow path protects the MicroSensor Card from blockages and downtime caused by blood clots. A safety sample port aspirates samples directly from syringes, tubes, cups, and ampoules, eliminating sample transfer steps and saving time. Acceptable samples include whole blood, serum, plasma, urine, and cerebrospinal fluid. Simple to operate with a colour touchscreen and built-in barcode scanner for positive patient ID, Stat Profile Prime ES may be used in a fixed location virtually anywhere in a hospital/clinic or operated on a mobile cart with a battery back-up. An optional 10-sample removable tray provides serial batch testing for serum, plasma, and urine samples. Prime ES patient results can be easily interfaced to the LIS/HIS with the industry standard POCT 1-A2 connectivity format.
Read more
Abbott has received the CE Mark for TriClip™ Transcatheter Tricuspid Valve Repair System which is now approved for use in Europe and other countries that recognize CE Mark. The device is used as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation (TR).
With the CE Mark designation, Abbott’s TriClip device is the first minimally invasive, clip-based tricuspid valve repair device to be commercially available in the world.
Abbott is a global leader in developing transcatheter treatments for heart valve disorders and has brought to market three first-in-class therapies for structural heart disease: MitraClip for mitral valve repair, Tendyne™ for mitral valve replacement, and now TriClip to treat the tricuspid valve.
The tricuspid valve, often referred to as the “forgotten heart valve”, has three leaflets that control the flow of blood between the two chambers on the right side of the heart. When those leaflets do not close properly, blood can flow in the reverse direction – known as regurgitation – forcing the heart to work harder. When left untreated, TR can lead to conditions such as atrial fibrillation, heart failure, and ultimately, death. The condition is difficult to treat, however, and options for patients have historically been extremely limited. People with TR are typically older and suffer from multiple co-morbidities, making open-heart surgery a high-risk procedure.
The TriClip procedure repairs the tricuspid valve without the need for open-heart surgery. The device is delivered to the heart through the femoral vein in the leg and works by clipping together a portion of the leaflets of the tricuspid valve to reduce the backflow of blood. This approach allows the heart to pump blood more efficiently, relieving symptoms of TR and improving a person’s quality of life.
“Patients suffering from severe tricuspid regurgitation are extremely ill and have very few treatment options,” said Georg Nickenig, M.D., Ph.D., professor and chief, Department of Cardiology, University Hospital, Bonn, Germany, and lead investigator of the TRILUMINATE trial, which generated strong data that helped lead to the CE Mark of TriClip. “Abbott’s TriClip could profoundly impact how physicians treat these patients. The therapy is backed by data proving safety and performance, durability, and improved patient quality of life.”
The CE Mark for TriClip follows positive six-month data from Abbott’s pivotal TRILUMINATE study examining edge-to-edge repair technique using TriClip, which was published in The Lancet in November 2019. The study demonstrated that TriClip reduced severity of TR and was associated with strong improvement in functional capacity and in quality of life at six months.
TriClip builds upon the proven success of Abbott’s MitraClip device, which treats people with leaky mitral valves, or mitral regurgitation (MR). TriClip leverages the same clip-based technology as MitraClip but has a differentiated delivery system designed specifically for delivery to the tricuspid valve. A new, steerable guiding catheter system adapts to the right side of the heart, where the tricuspid valve resides, enabling the physician to effectively grasp and clip the leaflets of the tricuspid valve. Additionally, the TriClip device is available in two different sizes (NT and XT) to accommodate different patient anatomies.
Read more
The Brevera breast biopsy system with CorLumina imaging technology combines tissue acquisition, real-time imaging, verification and advanced tissue handling for an optimal patient and physician experience. Before this innovation, radiologists performing stereotactic breast biopsy procedures to diagnose breast cancer were often required to leave the patient under compression while they moved to another room to image and verify tissue samples. This leads to lengthy procedure times and anxious, uncomfortable patients, and can interrupt facility screening schedules. With the Brevera system, radiologists are able to obtain and image tissue samples in the procedure room in just a few seconds, potentially saving up to 10 minutes per patient and cutting the procedure time by up to 25 percent according to the 2015 Kadence International survey of 200 healthcare professionals. In addition to saving facility resources and clinician time during a breast biopsy procedure, the Brevera system’s proprietary CorLumina imaging technology helps enhance workflow across multiple departments within a health system. The technology automates the tissue sample collection and separation process, which allows patient tissue to be sent to pathology with little or no manual handling, and also protects the integrity of samples. The system also features PACS integration for advanced image sharing and transfer of patient records.
Carestream Health has introduced a new optional advanced metal artifact reduction software for its OnSight 3D Extremity System which captures high-quality, low-dose 3D extremity exams. This second generation of software provides enhanced flexibility depending on the metal content present and reduces the visual distortion caused by screws, implants, rods and other metal objects to create improved visibility. Image processing can be adjusted and optimized according to the amount of metal present. The software uses information from the original scan to eliminate the need for additional imaging studies, which reduces costs and lowers radiation exposure for patients. An intuitive touch screen interface allows technologists to adjust for either moderate or complex metal content. The metal artifact reduction software can be activated prior to the scan or it can be applied after the original reconstruction is complete. Both the original and corrected images are always available to view and compare. The OnSight 3D Extremity System also assists surgeons in detecting occult and non-union bone fractures. Unlike traditional CT systems, this cone beam CT system has a large-area detector that captures a 3D image of the extremity in a single rotation, which takes only 25 seconds. A patient simply places the injured extremity into a donut-shaped opening in the system. Since the patient’s head and body are not confined, patients do not experience the claustrophobia that often occurs with traditional CT systems. Dose is significantly reduced because only the affected body part is imaged. The compact extremity system can be installed in an exam room and plugs into a standard wall outlet.
Read more
Siemens Healthineers recently announced the new RAPIDPoint 500e blood gas system, their latest solution in critical point-of-care testing. The new system generates blood gas, electrolyte and metabolyte results used to diagnose and monitor critically ill patients typically in the intensive care unit, operating room or emergency room. The RAPIDPoint 500e blood gas system is available now in all countries requiring the CE mark. Developed with extensive customer feedback, the system is designed to elevate confidence in patient results with Integri-sense technology, streamline workflow with improved simplicity and raise the bar in data security. Cybersecurity is becoming a key operational factor. Healthcare providers must protect confidential operator and patient information.
The RAPIDPoint 500e blood gas system incorporates Integri-sense technology, a comprehensive series of automated functional checks designed to deliver accurate test results at the point-of-care. Integri-sense technology combines three levels of automatic quality control (AutomaticQC), multiple calibration routines and advanced software algorithms to generate reliable and clinically actionable test results. It also integrates seamlessly into hospital networks with the Siemens Healthineers Point of Care Ecosystem which offers convenient, remote management of operators and devices located across multiple sites.
Two studies have been published that successfully evaluate the use of its Yumizen H500 hematology analyser for point-of-care testing (POCT) to enhance the care of oncology patients. With near-patient, full blood count results, patients undergoing chemotherapy can receive treatment without delay and greatly reduce their hospital/clinic exposure times. Both UK-based studies were presented at the recent ISLH 2018 (International Symposium on Technical Innovations in Laboratory Hematology) in Brussels.
The evaluation studies were performed by the Cardiff and Vale Health Board (CAVHB), University Hospital of Wales [1] and the Spire Bushey Laboratory, London [2] and can be viewed on the HORIBA Medical global website. Both studies demonstrated that the compact, easy-to-use analyser delivered at the POC clinically key parameters that showed exceptional correlation with larger laboratory-based hematology analysers. Blood samples from oncology patients may be abnormal, having low counts and atypical blood cells, therefore it is essential that near-patient testing does not compromise the clinical integrity of results.
The studies both found that in addition to speed and ease of use, the Yumizen H500’s functionality and audit systems fully adhere to ISO standards (both 15189:2012 and 22870:2016) with the same internal quality controls as larger analysers. This in turn ensured detailed, accurate results for timely and sound clinical decision making.
For example, the Cardiff study concluded that by using the Yumizen H500, “In CAVHB the potential for clinical improvement is potentially vast, average TAT (vein to report) for FBC is ~4 hours, this could be reduced to <15 minutes. This would mean that in certain patient groups (thrombocytopenic and anemic) they can request blood components earlier and be transfused more quickly, this in turn would reduce hospital stays. In neutropenic patients their treatment options could be considered more readily and reduce hospital/clinic exposure time in those that would not be appropriate for chemotherapy.” With just three reagents and an intuitive touch screen user interface, HORIBA Medical’s Yumizen H500 compact hematology analyser is designed for ease of use; yet it offers a range of clinically key parameters, including: 5-population WBC differential, red blood cell parameters and platelet count. This makes the Yumizen H500 most suitable for rapid blood counting for use in POC settings for pediatric care and chemotherapy patients, as well as from emergency care to the routine laboratory.
The two POCT studies presented at ISLH 2018 can be viewed at:
https://www.horiba.com/en_en/products/by-segment/medical/
April 2024
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.